Literature DB >> 20040006

Radial artery access as an emerging factor for decreasing mortality in cardiovascular interventions.

Cihan Cevik1, Cemil Izgi, Kenneth Nugent.   

Abstract

Transradial access for coronary interventions provides increased patient comfort, fewer access site complications, and reduced hospital stay and costs. However, the potential benefits favoring transradial access may be even more than these apparent advantages. Major bleeding after coronary interventions is an important factor contributing to mortality rates and can be dramatically reduced with the selection of the radial artery as the access site. Recent evidence suggests that the decrease in bleeding complications with transradial access may translate into a short- and long-term decrease in mortality in patients undergoing elective or urgent coronary interventions. In the era of complex coronary interventions with use of multiple antiplatelet and antithrombotic treatment regimens, the simple choice of transradial access for increasing patient comfort and decreasing bleeding complications and mortality is promising.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20040006     DOI: 10.1111/j.1540-8183.2009.00516.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  3 in total

1.  Repeated transradial catheterization: feasibility, efficacy, and safety.

Authors:  Marinos A Charalambous; Savvas S Constantinides; Michael A Talias; Elpidoforos S Soteriades; Christos P Christou
Journal:  Tex Heart Inst J       Date:  2014-12-01

2.  Is Radial Access and Transradial Cardiac Catheterization Feasible without the Use of Any Vasodilator?

Authors:  Cemil Izgi; Hasan Feray
Journal:  Int J Angiol       Date:  2014-03

3.  The effect of low dose versus standard dose of arterial heparin on vascular complications following transradial coronary angiography: Randomized controlled clinical trial.

Authors:  Farshad Roghani; Babak Shirani; Omid Hashemifard
Journal:  ARYA Atheroscler       Date:  2016-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.